Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

ABSTRACT:

Purpose

We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations.

Patient and methods

Patients with advanced cancer were treated in the Clinical Center for Targeted Therapy. Molecular analysis was conducted in the MD Anderson Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Patients whose tumors had an aberration were treated with matched targeted therapy, when available. Treatment assignment was not randomized. The clinical outcomes of patients with molecular aberrations treated with matched targeted therapy were compared with those of consecutive patients who were not treated with matched targeted therapy.

Results

Of

SUBMITTER: Tsimberidou AM 

PROVIDER: S-EPMC4454458 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature